These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31889506)

  • 21. Five-Year Impact of Different Multi-Year Mass Drug Administration Strategies on Childhood
    Shen Y; Wiegand RE; Olsen A; King CH; Kittur N; Binder S; Zhang F; Whalen CC; Secor WE; Montgomery SP; Mwinzi PNM; Magnussen P; Kinung'hi S; Campbell CH; Colley DG
    Am J Trop Med Hyg; 2019 Dec; 101(6):1336-1344. PubMed ID: 31407653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Persistent Hotspot of Schistosoma mansoni Infection in a Five-Year Randomized Trial of Praziquantel Preventative Chemotherapy Strategies.
    Wiegand RE; Mwinzi PNM; Montgomery SP; Chan YL; Andiego K; Omedo M; Muchiri G; Ogutu MO; Rawago F; Odiere MR; Karanja DMS; Secor WE
    J Infect Dis; 2017 Dec; 216(11):1425-1433. PubMed ID: 28968877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustaining Control of Schistosomiasis Mansoni in Western Côte d'Ivoire: Results from a SCORE Study, One Year after Initial Praziquantel Administration.
    Assaré RK; Tian-Bi YN; Yao PK; N'Guessan NA; Ouattara M; Yapi A; Coulibaly JT; Meïté A; Hürlimann E; Knopp S; Utzinger J; N'Goran EK
    PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004329. PubMed ID: 26789749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Profiling Nonrecipients of Mass Drug Administration for Schistosomiasis and Hookworm Infections: A Comprehensive Analysis of Praziquantel and Albendazole Coverage in Community-Directed Treatment in Uganda.
    Chami GF; Kontoleon AA; Bulte E; Fenwick A; Kabatereine NB; Tukahebwa EM; Dunne DW
    Clin Infect Dis; 2016 Jan; 62(2):200-7. PubMed ID: 26409064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential impact of mass and targeted praziquantel delivery on schistosomiasis control in school-aged children: A systematic review and meta-analysis.
    Cribb DM; Clarke NE; Doi SAR; Vaz Nery S
    PLoS Negl Trop Dis; 2019 Oct; 13(10):e0007808. PubMed ID: 31603895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can direct smear results that are routinely collected at health centre level be used for monitoring the impact of mass drug administration with praziquantel on schistosomiasis in Burundi? A preliminary assessment.
    Bizimana P; Polman K; Ortu G; Krit M; Nsabiyumva F; Nkeshimana A; Bijabuka U; Nibakire M; Van Geertruyden JP
    Parasit Vectors; 2020 Apr; 13(1):206. PubMed ID: 32317007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost of a school based mass treatment of schistosomiasis in Ugu District, KwaZulu Natal, South Africa in 2012.
    Maphumulo A; Mahomed O; Vennervald B; Gundersen SG; Taylor M; Kjetland EF
    PLoS One; 2020; 15(6):e0232867. PubMed ID: 32497049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Four Years of Annual Mass Drug Administration on Prevalence and Intensity of Schistosomiasis among Primary and High School Children in Western Kenya: A Repeated Cross-Sectional Study.
    Abudho BO; Ndombi EM; Guya B; Carter JM; Riner DK; Kittur N; Karanja DMS; Secor WE; Colley DG
    Am J Trop Med Hyg; 2018 May; 98(5):1397-1402. PubMed ID: 29532768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advocacy, policies and practicalities of preventive chemotherapy campaigns for African children with schistosomiasis.
    Stothard JR; Sousa-Figueiredo JC; Navaratnam AM
    Expert Rev Anti Infect Ther; 2013 Jul; 11(7):733-52. PubMed ID: 23879611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determining treatment needs at different spatial scales using geostatistical model-based risk estimates of schistosomiasis.
    Schur N; Vounatsou P; Utzinger J
    PLoS Negl Trop Dis; 2012; 6(9):e1773. PubMed ID: 23029570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Schistosoma mansoni on malaria transmission in Sub-Saharan Africa.
    Ndeffo Mbah ML; Skrip L; Greenhalgh S; Hotez P; Galvani AP
    PLoS Negl Trop Dis; 2014 Oct; 8(10):e3234. PubMed ID: 25329403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elimination of schistosomiasis requires multifactorial diagnostics: evidence from high- and low-prevalence areas in the Nile Delta, Egypt.
    Elmorshedy H; Bergquist R; Fayed A; Guirguis W; Abdel-Gawwad E; Eissa S; Barakat R
    Infect Dis Poverty; 2020 Apr; 9(1):31. PubMed ID: 32241298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of praziquantel mass drug administration campaign on prevalence and intensity of Schistosoma haemamtobium among school children in Bahi district, Tanzania.
    Chaula SA; Tarimo DS
    Tanzan J Health Res; 2014 Jan; 16(1):1-8. PubMed ID: 26867266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Schistosomiasis Consortium for Operational Research and Evaluation: Mission Accomplished.
    Bergquist NR
    Am J Trop Med Hyg; 2020 Jul; 103(1_Suppl):1-4. PubMed ID: 32400351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Schistosomiasis in African infants and preschool children: let them now be treated!
    Stothard JR; Sousa-Figueiredo JC; Betson M; Bustinduy A; Reinhard-Rupp J
    Trends Parasitol; 2013 Apr; 29(4):197-205. PubMed ID: 23465781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protocol and baseline data for a multi-year cohort study of the effects of different mass drug treatment approaches on functional morbidities from schistosomiasis in four African countries.
    Shen Y; King CH; Binder S; Zhang F; Whalen CC; Evan Secor W; Montgomery SP; Mwinzi PNM; Olsen A; Magnussen P; Kinung'hi S; Phillips AE; Nalá R; Ferro J; Aurelio HO; Fleming F; Garba A; Hamidou A; Fenwick A; Campbell CH; Colley DG
    BMC Infect Dis; 2017 Sep; 17(1):652. PubMed ID: 28962552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An inclusive dose pole for treatment of schistosomiasis in infants and preschool children with praziquantel.
    Sousa-Figueiredo JC; Day M; Betson M; Kabatereine NB; Stothard JR
    Trans R Soc Trop Med Hyg; 2010 Nov; 104(11):740-2. PubMed ID: 20832093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human schistosomiasis in the post mass drug administration era.
    Mutapi F; Maizels R; Fenwick A; Woolhouse M
    Lancet Infect Dis; 2017 Feb; 17(2):e42-e48. PubMed ID: 27988094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urogenital schistosomiasis infection prevalence targets to determine elimination as a public health problem based on microhematuria prevalence in school-age children.
    Wiegand RE; Fleming FM; Straily A; Montgomery SP; de Vlas SJ; Utzinger J; Vounatsou P; Secor WE
    PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009451. PubMed ID: 34115760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of global guidelines for preventive chemotherapy against schistosomiasis and soil-transmitted helminthiasis: a cost-effectiveness modelling study.
    Lo NC; Lai YS; Karagiannis-Voules DA; Bogoch II; Coulibaly JT; Bendavid E; Utzinger J; Vounatsou P; Andrews JR
    Lancet Infect Dis; 2016 Sep; 16(9):1065-1075. PubMed ID: 27286968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.